Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 9:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Methamphetamine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

NCT01359930
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
placebo, Naltrexone and Bupropion SR
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Phase 1 Interventional

Safety Interaction Trial Ibudilast and Methamphetamine

NCT01217970
View directory record Official record
Conditions
Methamphetamine-dependence, Substance Abuse
Interventions
Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 10, 2026, 9:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Drug Effects on Preference and Reward

NCT01722006
View directory record Official record
Conditions
Drug Addiction
Interventions
Pairing condition
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 10, 2026, 9:35 AM EDT
Terminated Early Phase 1 Interventional

Methamphetamine-Quetiapine Interactions in Humans

NCT00567866
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Quetiapine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Phase 1 Interventional

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

NCT01062451
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse, Substance Abuse
Interventions
Perindopril, Placebo, Candesartan
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 10, 2026, 9:35 AM EDT
Terminated Phase 1 Interventional

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

NCT05322954
View directory record Official record
Conditions
Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders, Substance Use Disorders, Stimulant-Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
25 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Phase 1 Interventional

Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence

NCT02034201
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Factors Affecting Methamphetamine and Opiates Drug Testing

NCT01736332
View directory record Official record
Conditions
Opiates, Healthy
Interventions
Vicks VapoInhaler, Poppy seeds
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 10, 2026, 9:35 AM EDT
Terminated Phase 1 Interventional

Study of Pomaglumetad and Methamphetamine

NCT03106571
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Pomaglumetad methionil, Placebo, Methamphetamine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Sep 10, 2026, 9:35 AM EDT
Not listed Phase 1 Interventional

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

NCT00267657
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Reserpine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

NCT03341078
View directory record Official record
Conditions
Methamphetamine-dependence
Interventions
Ibudilast, Placebo Oral Tablet
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 10, 2026, 9:35 AM EDT
Not yet recruiting Phase 4 Interventional

Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study

NCT07584369
View directory record Official record
Conditions
HIV -1 Infection, Methamphetamine Use
Interventions
Oral Methamphetamine, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Phase 4 Interventional Results available

Effect of Methamphetamine on Residual Latent HIV Disease Study

NCT03825536
View directory record Official record
Conditions
HIV-1-infection, Methamphetamine-dependence
Interventions
Oral Methamphetamine, Placebo oral capsule
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse

NCT01967381
View directory record Official record
Conditions
Methamphetamine Abuse, Methamphetamine Dependence
Interventions
Methamphetamine (Desoxyn®)
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 10, 2026, 9:35 AM EDT
Recruiting Early Phase 1 Interventional

Psilocybin for Methamphetamine Addiction

NCT06899594
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Psilocybin 25 mg
Drug
Lead sponsor
Kevin Murnane
Other
Eligibility
25 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Early Phase 1 Interventional Results available

PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)

NCT05128071
View directory record Official record
Conditions
Methamphetamine-dependence, Postpartum Abstinence
Interventions
Progesterone, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of Modafinil for Methamphetamine Dependence

NCT00569374
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Modafinil
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function

NCT05379959
View directory record Official record
Conditions
Stimulant Use, MDMA ('Ecstasy'), Social Behavior, Motivation
Interventions
MDMA, Methamphetamine, placebo oral tablet
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 10, 2026, 9:35 AM EDT
Not listed Phase 1 Interventional

Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

NCT00033072
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Varenicline vs Placebo for the Treatment of Methamphetamine Dependence

NCT01011829
View directory record Official record
Conditions
Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Studying Amphetamine Withdrawal in Humans

NCT01215929
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 10, 2026, 9:35 AM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin for Methamphetamine Use Disorder

NCT07774702
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct)., Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions).
Drug · Behavioral
Lead sponsor
Peter Hendricks
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Phase 2Phase 3 Interventional

Prometa Pharmacotherapy for Methamphetamine Dependence

NCT00260481
View directory record Official record
Conditions
Drug Abuse, Drug Dependence
Interventions
Prometa, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 10, 2026, 9:35 AM EDT
Completed Phase 1 Interventional

Rivastigmine as a Treatment for Methamphetamine Dependence

NCT01073319
View directory record Official record
Conditions
Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions
Placebo, Rivastigmine
Other · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 10, 2026, 9:35 AM EDT